A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...

By targeting a newly uncovered weakness in prostate cancer cells, this could offer an improved treatment for the disease.

There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific ...

Prostate cancer is the most common cancer among men after skin cancer, with approximately 1 in 8 men diagnosed in their lifetime.